Bob T. Li

20.5k total citations · 5 hit papers
147 papers, 4.6k citations indexed

About

Bob T. Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Bob T. Li has authored 147 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 94 papers in Pulmonary and Respiratory Medicine and 43 papers in Cancer Research. Recurrent topics in Bob T. Li's work include Lung Cancer Treatments and Mutations (82 papers), Cancer Genomics and Diagnostics (40 papers) and Lung Cancer Research Studies (31 papers). Bob T. Li is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Cancer Genomics and Diagnostics (40 papers) and Lung Cancer Research Studies (31 papers). Bob T. Li collaborates with scholars based in United States, Australia and Japan. Bob T. Li's co-authors include Jarushka Naidoo, David B. Page, Katja Schindler, Mario E. Lacouture, Louise C. Connell, Michael A. Postow, Jedd D. Wolchok, Mark G. Kris, Maria E. Arcila and Michael Offin and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Bob T. Li

138 papers receiving 4.6k citations

Hit Papers

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpo... 2015 2026 2018 2022 2015 2020 2024 2024 2024 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    2015 1.2k citations Bob T. Li et al. Annals of Oncology profile →
  2. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
    2020 248 citations Pasi A. Jänne, Bob T. Li et al. profile →
  3. Targeting KRAS in cancer
    2024 99 citations Bob T. Li et al. profile →
  4. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
    2024 76 citations Egbert F. Smit, Enriqueta Felip et al. The Lancet Oncology profile →
  5. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
    2024 43 citations Bob T. Li, Funda Meric‐Bernstam et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bob T. Li United States 31 3.3k 2.2k 1.1k 773 501 147 4.6k
Julia A. Beaver United States 39 2.7k 0.8× 1.5k 0.7× 1.1k 1.0× 1.1k 1.4× 519 1.0× 131 4.8k
Kirsten B. Goldberg United States 39 2.7k 0.8× 1.3k 0.6× 979 0.9× 711 0.9× 712 1.4× 66 4.5k
Erminia Massarelli United States 32 3.2k 1.0× 2.1k 1.0× 1.2k 1.2× 648 0.8× 729 1.5× 140 4.6k
Sang‐We Kim South Korea 36 3.5k 1.0× 3.9k 1.8× 1.4k 1.3× 743 1.0× 284 0.6× 207 5.4k
Lowell L. Hart United States 37 3.5k 1.0× 2.2k 1.0× 1.7k 1.6× 763 1.0× 257 0.5× 127 5.5k
Patrick M. Forde United States 40 4.0k 1.2× 2.7k 1.2× 934 0.9× 645 0.8× 1.1k 2.3× 186 5.7k
Christina S. Baik United States 27 2.1k 0.6× 1.8k 0.8× 1.3k 1.2× 685 0.9× 339 0.7× 116 3.5k
Simon Ekman Sweden 25 2.2k 0.6× 2.5k 1.1× 1.4k 1.3× 1.0k 1.3× 381 0.8× 116 4.2k
Sophie Postel‐Vinay France 37 3.2k 1.0× 1.7k 0.8× 2.2k 2.1× 936 1.2× 951 1.9× 117 5.7k
Dimitrios Bafaloukos Greece 34 3.0k 0.9× 1.6k 0.7× 1.2k 1.1× 867 1.1× 551 1.1× 132 4.5k

Countries citing papers authored by Bob T. Li

Since Specialization
Citations

This map shows the geographic impact of Bob T. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bob T. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bob T. Li more than expected).

Fields of papers citing papers by Bob T. Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bob T. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bob T. Li. The network helps show where Bob T. Li may publish in the future.

Co-authorship network of co-authors of Bob T. Li

This figure shows the co-authorship network connecting the top 25 collaborators of Bob T. Li. A scholar is included among the top collaborators of Bob T. Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bob T. Li. Bob T. Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Langer, Corey J., Rachel Galot, Hans Prenen, et al.. (2024). Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study.. Journal of Clinical Oncology. 42(16_suppl). 8559–8559. 1 indexed citations
2.
Liu, Dazhi, et al.. (2024). Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3129–3129. 1 indexed citations
3.
Hamilton, Erika, Gerald S. Falchook, Judy S. Wang, et al.. (2024). Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Targeted Oncology. 19(6). 879–892. 3 indexed citations
4.
Barlési, Fabrice, Enriqueta Felip, Sanjay Popat, et al.. (2024). Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).. Journal of Clinical Oncology. 42(16_suppl). TPS8653–TPS8653. 4 indexed citations
5.
Choudhury, Noura J., W. Victoria Lai, Alex Makhnin, et al.. (2024). A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer. Clinical Cancer Research. 30(17). 3697–3703. 14 indexed citations
6.
Li, Bob T., Jeffrey Clarke, Enriqueta Felip, et al.. (2024). Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.. Journal of Clinical Oncology. 42(16_suppl). 8512–8512. 8 indexed citations
7.
Tringale, Kathryn R., Anna Skakodub, Jacklynn V. Egger, et al.. (2024). Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases. JCO Precision Oncology. 8(8). e2300470–e2300470. 2 indexed citations
8.
Michelini, Flavia, Joshua Z. Drago, Dazhi Liu, et al.. (2024). EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Reports Medicine. 5(11). 101792–101792. 12 indexed citations
9.
Smit, Egbert F., Enriqueta Felip, Dipesh Uprety, et al.. (2024). Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. The Lancet Oncology. 25(4). 439–454. 76 indexed citations breakdown →
10.
Cabel, Luc, David M. Kurtz, Daniel W. Ross, et al.. (2024). 293P Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq. Annals of Oncology. 35. S338–S338. 1 indexed citations
11.
12.
Skakodub, Anna, Henry Walch, Kathryn R. Tringale, et al.. (2023). Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis. Nature Communications. 14(1). 4980–4980. 28 indexed citations
13.
Thummalapalli, Rohit, Bob T. Li, Afsheen N. Iqbal, et al.. (2023). Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology. 7(7). e2300030–e2300030. 23 indexed citations
14.
Isbell, James M., Bob T. Li, & Daniel R. Gomez. (2021). The emerging role of local therapy in oligometastatic non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 163(3). 819–825. 8 indexed citations
15.
Devarakonda, Siddhartha, Sumithra Sankararaman, Brett H. Herzog, et al.. (2019). Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. Clinical Cancer Research. 25(20). 6119–6126. 41 indexed citations
16.
Morikawa, Aki, Elisa de Stanchina, Elena Pentsova, et al.. (2019). Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. Clinical Cancer Research. 25(13). 3784–3792. 35 indexed citations
17.
Offin, Michael, Hira Rizvi, Megan Tenet, et al.. (2018). Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers. Clinical Cancer Research. 25(3). 1063–1069. 230 indexed citations
18.
Yu, Helena A., Ken Suzawa, Emmet Jordan, et al.. (2018). Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research. 24(13). 3108–3118. 188 indexed citations
19.
Kris, Mark G., D. Ross Camidge, Giuseppe Giaccone, et al.. (2015). Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Annals of Oncology. 26(7). 1421–1427. 221 indexed citations
20.
Li, Bob T., Dara S. Ross, Dara L. Aisner, et al.. (2015). HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. Journal of Thoracic Oncology. 11(3). 414–419. 212 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julia A. Beaver Breakdown of academic impact, for papers by Kirsten B. Goldberg Breakdown of academic impact, for papers by Erminia Massarelli Breakdown of academic impact, for papers by Sang‐We Kim Breakdown of academic impact, for papers by Lowell L. Hart Breakdown of academic impact, for papers by Patrick M. Forde Breakdown of academic impact, for papers by Christina S. Baik Breakdown of academic impact, for papers by Simon Ekman Breakdown of academic impact, for papers by Sophie Postel‐Vinay Breakdown of academic impact, for papers by Dimitrios Bafaloukos
Rankless by CCL
2026